Myocardial perfusion imaging

Myocardial perfusion imaging
Intervention

Myocardial perfusion scan with thallium-201 for the rest images (bottom rows) and Tc-Sestamibi for the stress images (top rows). The myocardial perfusion scan plays a pivotal role in the noninvasive evaluation of coronary artery disease. The study not only identifies some patients who have coronary artery disease, it can also provide overall prognostic information or overall risk of adverse cardiac events for the patient, provided that the patient does not suffer from Three-Vessel disease, the most serious result of coronary artery disease.
ICD-10-PCS C22G
MeSH D055414
OPS-301 code 3-704, 3-721

Myocardial perfusion scan (also referred to as MPI) is a nuclear medicine procedure that illustrates the function of the heart muscle (myocardium).[1]

It evaluates many heart conditions, such as coronary artery disease (CAD),[2] hypertrophic cardiomyopathy and heart wall motion abnormalities. The function of the myocardium is also evaluated by calculating the left ventricular ejection fraction (LVEF) of the heart. This scan is done in conjunction with a cardiac stress test.

Planar techniques, such as conventional scintigraphy, are rarely used. Rather, Single-photon emission computed tomography (SPECT) is more common in the US. With multihead SPECT systems, imaging can often be completed in less than 10 minutes. With SPECT, interior and posterior abnormalities and small areas of infarction can be identified, as well as the occluded blood vessels and the mass of infarcted and viable myocardium.[3]The usual isotopes for such studies are either Thallium-201 or Technetium-99m.

Major indications for a myocardial perfusion test

Risks vs. benefits

Experimental and epidemiologic evidence has linked exposure to low-dose ionizing radiation with up to 2% of solid cancers and leukemia. Workers are monitored and limited to 100 mSv every 5 years, but medical patients are not typically monitored.

From 1993-2001, myocardial perfusion scans increased >6%/y with "no justification," according to a commentary by Lauer. Mycardial perfusion imaging scans are "powerful predictors of future clinical events," and in theory may identify patients for whom aggressive therapies should improve outcome. But this is "only a hypothesis, not a proof," wrote Lauer. There are no randomized controlled trials to demonstrate any benefits, and there is a small but cumulative danger from radiation.[4]

New radionuclides such as rubidium-82 reduce the radiation dose to the patient by a factor of 10 compared to technetium-99m. In the future, therefore, a complete myocardial perfusion exam may be achievable while maintaining a patient dose under 3 mSv.[5][6] Stress-only protocols may also prove to be effective at reducing costs and patient exposure.[7]

References

  1. ↑ Myocardial Perfusion Imaging at the US National Library of Medicine Medical Subject Headings (MeSH)
  2. ↑ Lee, J. C.; West, M. J.; Khafagi, F. A. (2013). "Myocardial perfusion scans". Australian family physician. 42 (8): 564–7. PMID 23971065.
  3. ↑ Merck manuals > Radionuclide Imaging Last full review/revision May 2009 by Michael J. Shea, MD. Content last modified May 2009
  4. ↑ Perspective: Elements of danger -- the case of medical imaging, Michael S. Lauer, N Engl J Med, 27 Aug 2009, 361(9):841.
  5. ↑ A revised effective dose estimate for the PET perfusion tracer Rb-82, deKemp et al, J NUCL MED MEETING ABSTRACTS, 2008. 49(MeetingAbstracts_1): p. 183P-b-.
  6. ↑ Radiopharmaceuticals for nuclear cardiology: radiation dosimetry, uncertainties, and risk., Stabin et al, J Nucl Med, 2008. 49(9): p. 1555-63.
  7. ↑ Stress-only Nuclear Myocardial Perfusion Imaging, Heston TF, Internet Med J, accessed 17-Feb-2012.
This article is issued from Wikipedia - version of the 6/3/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.